| Literature DB >> 29033435 |
Maiko Naito1, Toshiya Maekura1, Yu Kurahara1, Masahiro Tahara1, Naoya Ikegami1, Yohei Kimura1, Shoko Sonobe1, Takehiko Kobayashi1, Shojiro Minomo1, Taisuke Tsuji1, Kazunari Tsuyuguchi2, Seiji Hayashi1, Katsuhiro Suzuki1.
Abstract
Objective The incidence of pulmonary nontuberculous mycobacterial (NTM) infections has increased in recent decades. Nevertheless, NTM pleurisy is still a rare disease. The objective of the present study was to elucidate the clinical features and outcomes of NTM pleurisy. Methods A retrospective study was undertaken of consecutive patients whose pleural effusion culture yielded NTM, from 2002 to 2016 at a respiratory hospital in Japan. The clinical features, treatment, and outcomes of these patients were analyzed. Result The 12 patients with NTM pleurisy were predominantly male, with a median age of 69 years (range, 48-93 years). They included eight patients with a history of smoking and six patients with immunosuppressive comorbidities such as malignancy, diabetes mellitus, and conditions requiring steroid administration. Fibrocavitary disease was the most common radiographic feature of these patients, and Mycobacterium avium complex was the most common pathogen. Pneumothorax was complicated in 11 patients. Surgery was performed on seven patients, in addition to thoracic drainage for the treatment of pleurisy and pneumothorax. Three patients died of respiratory failure. Conclusion Pneumothorax is a frequent complication of NTM pleurisy, often making the condition difficult to treat. Surgery at an appropriate time should therefore considered for refractory cases.Entities:
Keywords: nontuberculous mycobacterium; pleurisy; pneumothorax
Mesh:
Year: 2017 PMID: 29033435 PMCID: PMC5799050 DOI: 10.2169/internalmedicine.9119-17
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Patient Characteristics (n=12).
| Age, years, median (range) | 69 | (48-93) | |
| Sex | |||
| Male | 9 | ||
| Female | 3 | ||
| Smoking history | |||
| Yes | 8 | ||
| No | 4 | ||
| Immunosuppressed factor | |||
| Malignancy | 1 | ||
| Diabetes mellitus | 4 | ||
| Steroid administration | 3 | ||
| Body mass index, kg/m2, median (range) | 21.2 | (15.4-22.5) | |
| Laboratory (serum) | median | (range) | |
| WBC, /μL | 7,500 | (2,100-14,200) | |
| Hb, g/dL | 11.8 | (8.5-14.5) | |
| TP, g/dL | 7.1 | (5.2-7.9) | |
| Alb, g/dL | 3.2 | (2.1-4.2) | |
| CRP, mg/dL | 7.1 | (2.2-26.9) | |
| Appearance of pleural effusion | |||
| Yellow | 4 | ||
| Bloody | 1 | ||
| Purulent | 1 | ||
| Unknown | 6 | ||
| Predominant cell of pleural effusion | |||
| Lymphocyte | 5 | ||
| Neutrophil | 2 | ||
| Unknown | 5 | ||
| Laboratory (pleural effusion) | median | (range) | |
| pH | 7.2 | (7.0-7.4) | |
| LDH, U/L | 760 | (256-8,970) | |
| Glucose, mg/dL | 93 | (1-238) | |
| Total protein, g/dL | 4.2 | (3.3-5.2) | |
| ADA, U/L | 59.8 | (29.8-73.2) | |
Radiologic Findings (n=12).
| Disease type | ||
| NB | 3 | |
| FC | 5 | |
| Unknown | 4 | |
| Cavity | ||
| Right | 6 | |
| Left | 0 | |
| Bilateral | 2 | |
| Unknown | 4 | |
| Pneumothorax | ||
| Right | 8 | |
| Left | 3 | |
| None | 1 | |
NB: nodular/ bronchiectatic disease, FC: fibrocavitary disease
Patients with Nontuberculosis Pleurisy (n=12).
| Case | Age, sex | Mycobacterium species (PE) | Medical history | Medication before onset | Medication after onset | Time until onset of plerisy from diagnosis of NTM | Pneumothorax | Treatment other than medication | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 59, M | RA | INH, RFP, EB, PZA | INH, RFP, EB, PZA | same time | (+) | drainage+surgery | improved | |
| 2 | 69, M | SCLC, Radiation pneumonitis | none | none | unknown | (-) | none | death | |
| 3 | 72, M | Urinary calculus | RFP, EB, CAM | RFP, EB, CAM | 4 years 7 months | (+) | drainage+surgery | improved | |
| 4 | 93, F | Osteoporosis | RFP, EB, CAM | RFP, EB, CAM | 1 year 8 months | (+) | drainage | improved | |
| 5 | 60, M | DM, Tb | none | RFP, EB, CAM | same time | (+) | drainage+surgery | improved | |
| 6 | 77, M | ICH, HT, Liver cirrhosis | none | none | unkown | (+) | none | no change | |
| 7 | 48, M | Pneumothorax | RFP, EB, CAM | RFP, EB, CAM | 1month | (+) | drainage+surgery | improved | |
| 8 | 69, F | none | RFP, CAM, STFX | RFP, CAM, AMK | 18 years 10 months | (+) | drainage | death | |
| 9 | 71, M | DM, OMI, Asthma | RFP, EB, CAM | RFP, EB, CAM | 4 years 9 months | (+) | drainage+surgery | death | |
| 10 | 84, M | DM, OMI | RFP, EB | RFP, EB, CAM | 4 months | (+) | drainage | improved | |
| 11 | 61, F | HT, Aspergillosis | RFP, EB, CAM | RFP, EB, CAM, SM | 4 years 2 months | (+) | drainage+surgery | improved | |
| 12 | 66, M | DM, Chronic hepatitis C, COPD, IPF | none | RFP, EB, CAM | 3 years 9 months | (+) | drainage+surgery | improved |
RA: Rheumatoid arthritis, SCLC: Small cell lung cancer, DM: Diabetes mellitus, Tb: Pulmonary tuberculosis, ICH: Intracerebral hemorrhage, HT: Hypertension, OMI: Old myocardial infarction, COPD: Chronic obstructive pulmonary disease, IPF: Idiopathic pulmonary fibrosis, INH: Isoniazid, RFP: Rifampicin, EB: Ethambutal, PZA: Pyrazinamide, CAM: clarithromycin, STFX: Sitafloxacin, AMK: Amikacin, SM: Streptomycin